Protocol Adaptations
Cross-source consensus on Protocol Adaptations from 1 sources and 5 claims.
1 sources · 5 claims
Background
Highlighted claims
- The COVID-19 pandemic required multiple protocol adaptations. — Real-world and Genomic data-based Asthma Insights through Network Analysis (REGAIN study): protocol for a novel retrospective and prospective longitudinal asthma cohort study
- All study activity paused from March 9, 2020 through June 25, 2020. — Real-world and Genomic data-based Asthma Insights through Network Analysis (REGAIN study): protocol for a novel retrospective and prospective longitudinal asthma cohort study
- National Jewish Health was added as a study site in September 2021. — Real-world and Genomic data-based Asthma Insights through Network Analysis (REGAIN study): protocol for a novel retrospective and prospective longitudinal asthma cohort study
- Pulmonary function testing was unavailable from March 2020 into late 2021 because of infection-control measures. — Real-world and Genomic data-based Asthma Insights through Network Analysis (REGAIN study): protocol for a novel retrospective and prospective longitudinal asthma cohort study
- The protocol removed type 2 biomarker requirements for stable biologic and de novo biologic groups after tezepelumab approval. — Real-world and Genomic data-based Asthma Insights through Network Analysis (REGAIN study): protocol for a novel retrospective and prospective longitudinal asthma cohort study